Cardiovascular safety of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study-Reference-Cited by-同舟云学术

Cardiovascular safety of antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study

Published:2019-09-30 Issue:1 Volume:12 Page:68-80
ISSN:1757-5664
Container-title:LUTS: Lower Urinary Tract Symptoms
language:en
Short-container-title:Lower Urinary Tract Symptoms

Author:

Katoh Takao¹,Igawa Yasuhiko²,Yamaguchi Osamu³,Kato Daisuke⁴,Hamada Takuya⁴,Kuroishi Kentaro⁴

Affiliation:

1. Cardiovascular Center, Mita HospitalInternational University of Health and Welfare Tokyo Japan

2. Department of Continence MedicineThe University of Tokyo Graduate School of Medicine Tokyo Japan

3. Department of Chemical Biology and Applied ChemistryNihon University School of Engineering Koriyama Japan

4. Astellas Pharma Inc. Tokyo Japan

Funder

Astellas Pharma Global Development

Publisher

Wiley

Subject

Urology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/luts.12286

Reference34 articles.

1. An epidemiological survey of overactive bladder symptoms in Japan

2. Presence of central nervous system, cardiovascular and overall co-morbidity burden in patients with overactive bladder disorder in a real-world setting

3. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder

4. An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder

5. Muscarinic receptor antagonists for overactive bladder

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults;Cochrane Database of Systematic Reviews;2023-05-09

2. Mirabegron in the Management of Overactive Bladder Syndrome;International Journal of Women's Health;2022-09

3. Chronic bladder diseases: overactive bladder and interstitial cystitis/bladder pain syndrome;Journal of the Korean Medical Association;2021-11-10

4. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?;Current Urology Reports;2020-10-22